查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014923

肝病治疗市场：2026-2030年全球市场预测（依疾病、治疗方法、给药途径、药物类别、最终用户和分销管道划分）

Liver Diseases Therapeutics Market by Disease Type, Therapy Type, Route Of Administration, Drug Class, End User, Distribution Channel - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年肝病治疗市场价值为 187.6 亿美元，预计到 2025 年将成长至 202.6 亿美元，复合年增长率为 8.13%，到 2030 年将达到 300 亿美元。

主要市场统计数据
基准年 2024 187.6亿美元
预计年份：2025年 202.6亿美元
预测年份：2030年 300亿美元
复合年增长率 (%) 8.13%

对目前肝病治疗策略的现状和未来可能性进行详细考察，以应对肝病带来的挑战。

随着肝病盛行率和复杂性的不断增加，迫切需要能够有效应对各种急慢性肝病的创新治疗策略。儘管传统疗法长期以来依赖抗病毒药物和支持性治疗，但近年来，随着对纤维化机制、免疫调节和细胞再生认识的不断深入，肝病治疗领域正在发生显着变化。本文探讨了跨学科研究、先进的生物技术平台和以患者为中心的治疗模式如何融合，进而重塑肝病治疗。

近期科学突破和以病人为中心的创新如何重新定义肝病治疗的方法和结果？

过去十年，科学突破彻底改变了我们对肝臟疾病的理解和治疗。基因疗法的创新为纠正潜在的遗传易感性提供了可能，而细胞疗法和再生医学的进步则为恢復肝功能提供了新的策略。同时，微生物组调节疗法的引入，透过利用肠道-肝轴的相互作用来减少发炎和纤维化，从而重新定义了肝臟疾病的治疗模式。

评估 2025 年美国关税措施对肝病治疗药物的研发、供应链和取得的广泛影响。

美国将于2025年实施关税，将为全球肝病治疗供应链带来新的复杂性。从海外采购原料（包括基因和细胞疗法所需的特殊生物成分和试剂）的成本压力日益增加。随着製造成本的上升，相关人员面临着如何在不牺牲品质或可及性的前提下维持价格竞争力的挑战。

透过对疾病类型、治疗方法、给药途径、药物类别、使用环境和分销管道进行多方面细分，揭示关键见解。

精准了解患者亚群对于制定个人化的肝病治疗性介入至关重要。疾病类型细分涵盖了从酒精性肝病到慢性病毒感染疾病（如乙型和丙型肝炎）的全部范围，以及肝癌亚型（如肝细胞癌和胆管​​癌）和日益增长的非酒精性脂肪性肝病。每一类疾病都有其独特的病理学机转和临床管理考量。

检验美洲、欧洲、中东和非洲以及亚太地区肝病治疗创新、取得和传播的区域趋势和具体影响因素。

区域趋势对肝病治疗方法的引入、发展和可近性有显着影响。在美洲，健全的法规结构和完善的临床试验网络正在加速先进生技药品和基因疗法的引入。医疗保健系统日益注重以价值为导向的医疗服务，从而推动了对那些与现有标准疗法相比能够展现出明显临床和经济效益的治疗方法的需求。

透过研究和合作，我们概述了在全球肝病治疗领域推动创新、伙伴关係和策略成长的最具影响力的组织。

肝病治疗市场由一群主要企业主导，这些企业透过广泛的研发管线、策略伙伴关係和有针对性的收购来推动创新。成熟的製药公司继续利用其全球研发能力推进大规模临床项目，而新兴生物技术公司则专注于高影响力细分领域，例如遗传代谢疾病的基因矫正和肝癌的个人化免疫疗法。

肝病治疗药物研发与交付领域的产业领导者面临的策略挑战：抓住新机会、降低风险、促进永续成长。

产业领导者必须采取果断行动，最大限度地掌握肝病治疗领域的新兴机会。首先，投资灵活的生产平台，能够减少供应链中断，并提高应对力关税成本压力的能力，从而确保患者获得不间断的治疗。各机构应探索伙伴关係，利用风险共担机制进行细胞和基因疗法的共同研发，在降低成本的同时加速临床开发进程。

本书汇集了关键亮点和策略考量，阐明了创新治疗方法、协作方法和政策考量在推进肝病治疗中的关键作用。

本执行摘要整合了定义肝病治疗现状及未来的关键趋势、关税的影响、细微的市场区隔差异、区域驱动因素以及主要组织策略。先进的生技药品平台、基因编辑技术和以患者为中心的治疗模式的融合，正在重塑从病毒性肝炎到复杂肝细胞癌等多种疾病的治疗前景。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 肝病治疗市场：依疾病类型划分

  • 酒精性肝臟疾病
  • B型肝炎
  • C型肝炎
  • 肝癌
    • 胆管癌
    • 肝细胞癌
  • 非酒精性肝臟疾病

第九章 肝病治疗市场：依治疗方法

  • 生物免疫疗法
  • 细胞疗法和再生医学
  • 基因治疗
  • 微生物组调节疗法
  • 小分子药物

第十章 肝病治疗市场：依给药途径划分

  • 静脉
  • 口服
  • 皮下

第十一章 肝病治疗市场：依药物类别划分

  • 抗纤维化药物
    • Pirfenidone
    • 辛妥珠单抗
  • 抗病毒药物
    • 干扰素
    • NS5A抑制剂
    • NS5B聚合酵素抑制剂
    • 核苷酸/核苷类似物
    • 蛋白酶抑制剂
  • 化疗药物
  • 皮质类固醇
  • 免疫抑制剂
  • 单株抗体

第十二章 肝病治疗市场：依最终用户划分

  • 诊所
  • 居家照护
  • 医院

第十三章 肝病治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十四章 肝病治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 肝病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 肝病治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国肝病治疗市场

第十八章：中国肝病治疗市场

第十九章 竞争情势

  • 2024年市场集中度分析
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2024 年
  • 2024年产品系列分析
  • 基准分析，2024 年
  • AbbVie Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genfit SA
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Intercept Pharmaceuticals, Inc.（Alfasigma SpA）
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-437A5D08AE2A

The Liver Diseases Therapeutics Market was valued at USD 18.76 billion in 2024 and is projected to grow to USD 20.26 billion in 2025, with a CAGR of 8.13%, reaching USD 30.00 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 18.76 billion
Estimated Year [2025] USD 20.26 billion
Forecast Year [2030] USD 30.00 billion
CAGR (%) 8.13%

An In-Depth Exploration of the Current State and Future Potential in Therapeutic Strategies for Addressing Liver Disease Challenges

The escalating prevalence and complexity of liver diseases present an urgent imperative for innovative therapeutic strategies that can effectively address the spectrum of chronic and acute hepatic conditions. While traditional approaches have long relied on antiviral agents and supportive care, recent years have witnessed a profound shift driven by deeper insights into fibrotic mechanisms, immune modulation, and cellular regeneration. This introduction explores how multidisciplinary research, advanced biotechnology platforms, and patient-centered frameworks are converging to reshape the therapeutic landscape.

Throughout this report, attention is devoted to understanding how novel platforms-ranging from next-generation biologic immunotherapies to the precision of gene editing-are targeting pathophysiological pathways with unprecedented specificity. As the pipeline expands, comprehensive analyses will examine factors such as the evolving regulatory environment, supply chain resilience in light of new tariff policies, and synergies between established pharmaceutical players and emerging biotech innovators.

By presenting an integrated overview of strategic dynamics and emerging opportunities, this section sets the stage for a deeper exploration of transformative shifts, tariff implications, segmentation insights, and regional drivers that collectively inform strategic decision-making in the field of liver disease therapeutics.

How Recent Scientific Breakthroughs Coupled with Patient-Centric Innovations Are Redefining Therapeutic Approaches and Outcomes in Liver Disease Care

Over the past decade, scientific breakthroughs have catalyzed transformative shifts in how liver diseases are understood and managed. Innovations in gene therapy are unlocking the potential to correct underlying genetic predispositions, while advancements in cell-based and regenerative therapies are offering strategies to restore hepatic function. Concurrently, the introduction of microbiome-modulating therapies is redefining paradigms by harnessing gut-liver axis communications to attenuate inflammation and fibrosis.

In addition to technological leaps, patient-centric approaches are gaining prominence. Personalized immunotherapeutic regimens, informed by individual biomarker profiles, are enhancing efficacy and reducing adverse events. Furthermore, strategic alliances between pharmaceutical companies and academic research centers are accelerating translational efforts, resulting in streamlined clinical development pathways and more robust evidence generation.

As a result of these converging forces, liver disease therapeutics are transitioning from reactive symptom management toward proactive disease modification and potential reversal of hepatic damage. This section examines the catalysts driving this evolution, including shifts in regulatory expectations, expanded access programs, and the rising importance of real-world evidence in shaping therapeutic value propositions.

Assessing the Far-Reaching Consequences of the 2025 United States Tariff Measures on the Development, Supply Chains, and Accessibility of Liver Disease Treatments

The introduction of United States tariff measures in 2025 has introduced new complexities into the global supply chains for therapeutic agents targeting liver conditions. Raw materials sourced from overseas, including specialized biologic components and reagents for gene and cell therapies, have experienced increased cost pressures. As manufacturing expenses rise, stakeholders face challenges in maintaining competitive pricing structures without compromising quality or accessibility.

Moreover, these tariffs have prompted companies to reassess their sourcing strategies, with some opting to diversify suppliers or establish local production capabilities. Such shifts carry implications for production timelines, regulatory compliance, and inventory management. In parallel, research collaborations that depend on cross-border exchanges of proprietary materials and technologies are navigating a more intricate tariff landscape that demands enhanced logistical coordination.

Despite these headwinds, the tariff environment has also spurred greater investment in domestic manufacturing infrastructure and encouraged the exploration of alternative raw-material platforms. By evaluating the cumulative impact of these measures, industry leaders can develop resilient strategies that safeguard continuity of supply, optimize cost structures, and ensure ongoing patient access to critical liver disease therapies.

Unveiling Critical Insights from Multi-Dimensional Segmentation Across Disease Types, Therapeutic Modalities, Administration Routes, Drug Classes, User Settings, and Distribution Channels

A nuanced understanding of patient subpopulations is foundational to tailoring therapeutic interventions for liver diseases. Segmentation based on disease type captures the full spectrum from Alcoholic Liver Disease to chronic viral infections such as Hepatitis B and Hepatitis C, as well as hepatocellular and cholangiocarcinoma subtypes of liver cancer and the increasingly prevalent Non-Alcoholic Liver Disease. Each of these categories presents unique pathophysiological mechanisms and clinical management considerations.

Equally critical is analyzing the therapeutic modalities under investigation. Biologic immunotherapies are leveraging checkpoint inhibition and cytokine modulation, while cell-based and regenerative approaches seek to replace or repair damaged hepatic tissue. Gene therapies are poised to address inherited metabolic disorders, and microbiome-modulating interventions aim to restore gut-liver axis equilibrium. Meanwhile, the continued refinement of small-molecule compounds ensures a diverse arsenal against fibrotic and inflammatory pathways.

Routes of administration influence both patient adherence and pharmacokinetic profiles, with intravenous infusions facilitating high-dose or acute interventions, oral formulations providing convenience for chronic regimens, and subcutaneous injections offering a middle ground between efficacy and ease of use. Alongside these considerations, drug classes such as antifibrotic agents-encompassing molecules like pirfenidone and simtuzumab-and a range of antiviral compounds, including interferons and NS5A inhibitors, each play distinct roles in interrupting disease progression.

Finally, understanding the contexts in which therapies are delivered is essential. End users span from specialized clinics to home care settings and hospital environments, necessitating flexible treatment protocols and support infrastructures. Distribution channels, whether via hospital pharmacies, online dispensaries, or retail outlets, further shape access dynamics and patient experiences.

Examining Regional Dynamics and Unique Drivers Across the Americas, Europe Middle East & Africa, and Asia-Pacific That Influence Therapeutic Innovation, Access, and Adoption in Liver Disease Care

Regional dynamics exert a powerful influence on the adoption, development, and accessibility of liver disease therapies. In the Americas, strong regulatory frameworks and established clinical trial networks have accelerated the introduction of advanced biologics and gene therapies. Healthcare systems are increasingly focused on value-based care initiatives, driving demand for treatments that can demonstrate clear clinical and economic benefits over existing standards.

Europe, the Middle East, and Africa present a diverse landscape shaped by varying healthcare infrastructures and policy environments. Within this region, collaborative consortia have facilitated cross-border clinical studies, while multinational reimbursement pathways continue to evolve. Emerging economies are investing in expanded diagnostic and treatment capacities, creating new opportunities for therapies targeting both viral hepatitis and non-alcoholic steatohepatitis.

In Asia-Pacific, robust government support for research and development, combined with high prevalence rates of both viral and metabolic liver diseases, has cultivated a fertile environment for innovation. Local biotech enterprises are partnering with global pharmaceutical leaders to co-develop novel interventions, and patient access programs are adapting to the unique socioeconomic conditions across the region.

Together, these regional insights underscore the importance of tailored strategies that align regulatory, economic, and healthcare delivery considerations with the specific needs and drivers of each market.

Profiling the Most Influential Organizations Driving Innovation, Partnerships, and Strategic Growth in the Global Liver Disease Therapeutics Arena Through Research and Collaborations

The liver disease therapeutics landscape is shaped by a constellation of leading companies that drive innovation through expansive research pipelines, strategic partnerships, and targeted acquisitions. Established pharmaceutical entities continue to leverage their global development capabilities to advance large-scale clinical programs, while emerging biotechs are focusing on high-impact niches such as gene correction for inherited metabolic disorders and personalized immunotherapies for liver cancer.

Collaborative networks between academic institutions and industry players are increasingly prolific, enabling the rapid translation of preclinical discoveries into early-phase clinical trials. In parallel, alliances with contract manufacturing organizations are enhancing production scalability for complex biologics and cell therapies. The pursuit of orphan drug designations and accelerated approval pathways further illustrates how companies are navigating regulatory landscapes to bring breakthrough treatments to patients more swiftly.

Innovation is complemented by strategic investments in advanced manufacturing technologies, including closed-system bioreactors and automated cell processing, which collectively reduce production bottlenecks and improve batch consistency. Concurrently, players across the spectrum are exploring digital health integrations-from remote patient monitoring to AI-driven biomarker analysis-that have the potential to refine clinical development and broaden access.

Through a combination of in-house research excellence, external collaborations, and forward-looking technology adoption, these key companies are at the forefront of transforming liver disease treatment paradigms.

Strategic Imperatives for Industry Leaders to Capitalize on Emerging Opportunities, Mitigate Risks, and Foster Sustainable Growth in Liver Disease Therapeutic Development and Delivery

Industry leaders must act decisively to capitalize on emerging opportunities within liver disease therapeutics. First, investing in flexible manufacturing platforms will mitigate supply chain disruptions and enhance responsiveness to tariff-induced cost pressures, thereby safeguarding uninterrupted patient access. Organizations should evaluate partnerships that enable co-development of cell and gene therapies with shared risk models to accelerate clinical advancement while controlling expenses.

Second, adopting a patient-centric development framework will strengthen real-world evidence generation, optimize trial design, and improve adherence. Tailoring protocols to accommodate home care administration and digital health support can differentiate offerings and align with evolving care delivery trends. In parallel, leveraging biomarkers to stratify patient populations will increase the probability of clinical success and support value-based pricing discussions.

Third, proactive engagement with regulatory agencies across key regions will facilitate alignment on accelerated approval pathways and post-market surveillance requirements. Companies should establish cross-functional regulatory task forces that integrate global policy insights, ensuring that development strategies are robust and adaptable.

By executing on these strategic imperatives, industry leaders can drive sustainable growth, enhance therapeutic impact, and maintain a competitive advantage in the rapidly evolving field of liver disease care.

The insights presented in this report are built upon a rigorous, multi-layered research methodology designed to ensure accuracy, relevance, and comprehensive coverage of the liver disease therapeutics landscape. Primary research forms the backbone of our analysis, incorporating in-depth interviews with key opinion leaders, clinical investigators, regulatory specialists, and senior executives within pharmaceutical and biotech companies.

Complementing these qualitative insights, secondary research draws from peer-reviewed journals, clinical trial registries, patent filings, and regulatory documents to validate pipeline developments and technology trends. Data from publicly available corporate reports, scientific conferences, and institutional repositories further enrich the contextual understanding of competitive dynamics.

Analytical frameworks, including SWOT assessments and PESTEL evaluations, have been applied to interpret strategic positioning, innovation drivers, and external influences such as tariff policies. Triangulation of qualitative and quantitative data ensures that findings are cross-verified and free from bias.

Finally, ongoing validation through expert workshops and scenario analyses enhances the robustness of conclusions and recommendations, providing stakeholders with a dependable foundation for strategic planning and investment decisions.

Synthesis of Key Findings and Strategic Reflections That Highlight the Pivotal Role of Innovative Therapies, Collaborative Efforts, and Policy Considerations in Advancing Liver Disease Treatment

This executive summary has synthesized the critical trends, tariff implications, segmentation nuances, regional drivers, and key organizational strategies that define the current and future state of liver disease therapeutics. The convergence of advanced biologic platforms, gene editing technologies, and patient-centric delivery models is reshaping treatment possibilities for conditions ranging from viral hepatitis to complex hepatocellular carcinomas.

By examining the cumulative impact of United States tariff measures, this report underscores the importance of resilient supply chain strategies and diversified manufacturing approaches. Segmentation analyses reveal distinct treatment pathways tailored to varied disease subtypes, therapeutic mechanisms, and delivery environments, while regional insights highlight the need for market-specific strategies informed by local healthcare infrastructures and regulatory landscapes.

Strategic recommendations emphasize the value of collaborative development models, patient-data integration, and proactive regulatory engagement. Together, these elements form a cohesive roadmap for stakeholders to navigate challenges, seize opportunities, and drive continued innovation in liver disease care.

In conclusion, the accelerated pace of scientific and policy evolution calls for decisive, informed action to translate research breakthroughs into tangible clinical benefits and deliver sustainable value to patients and healthcare systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Diseases Therapeutics Market, by Disease Type

  • 8.1. Alcoholic Liver Disease
  • 8.2. Hepatitis B
  • 8.3. Hepatitis C
  • 8.4. Liver Cancer
    • 8.4.1. Cholangiocarcinoma
    • 8.4.2. Hepatocellular Carcinoma
  • 8.5. Non Alcoholic Lever Disease

9. Liver Diseases Therapeutics Market, by Therapy Type

  • 9.1. Biologic Immunotherapies
  • 9.2. Cell-Based & Regenerative Therapy
  • 9.3. Gene Therapy
  • 9.4. Microbiome-Modulating Therapies
  • 9.5. Small-Molecule Drugs

10. Liver Diseases Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Liver Diseases Therapeutics Market, by Drug Class

  • 11.1. Antifibrotic
    • 11.1.1. Pirfenidone
    • 11.1.2. Simtuzumab
  • 11.2. Antivirals
    • 11.2.1. Interferons
    • 11.2.2. NS5A Inhibitors
    • 11.2.3. NS5B Polymerase Inhibitors
    • 11.2.4. Nucleotide/Nucleoside Analogues
    • 11.2.5. Protease Inhibitors
  • 11.3. Chemotherapeutic
  • 11.4. Corticosteroids
  • 11.5. Immunosuppressants
  • 11.6. Monoclonal Antibody

12. Liver Diseases Therapeutics Market, by End User

  • 12.1. Clinic
  • 12.2. Home Care Settings
  • 12.3. Hospital

13. Liver Diseases Therapeutics Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Liver Diseases Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Liver Diseases Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Liver Diseases Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Liver Diseases Therapeutics Market

18. China Liver Diseases Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. AbbVie Inc.
  • 19.6. Alnylam Pharmaceuticals, Inc.
  • 19.7. Astellas Pharma Inc.
  • 19.8. AstraZeneca PLC
  • 19.9. Bristol-Myers Squibb Company
  • 19.10. C. H. Boehringer Sohn AG & Co. KG
  • 19.11. Eli Lilly and Company
  • 19.12. F. Hoffmann-La Roche Ltd.
  • 19.13. Genfit S.A.
  • 19.14. Gilead Sciences, Inc.
  • 19.15. GlaxoSmithKline plc
  • 19.16. Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
  • 19.17. Johnson & Johnson Services Inc.
  • 19.18. Merck & Co., Inc.
  • 19.19. Moderna, Inc.
  • 19.20. Novartis AG
  • 19.21. Pfizer Inc.
  • 19.22. Sanofi SA
  • 19.23. Takeda Pharmaceutical Company Limited
  • 19.24. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 14. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 82. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 83. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 85. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 86. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 88. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 90. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 91. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 93. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 95. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 96. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 97. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 98. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 100. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 101. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 105. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 106. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 108. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 111. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 112. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 114. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 115. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 117. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 121. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 122. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 127. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 131. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 132. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. NORTH AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 137. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 141. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 142. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. LATIN AMERICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 162. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. EUROPE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 165. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 167. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 171. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 172. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. MIDDLE EAST LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 175. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 177. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 181. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 182. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 196. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 198. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 201. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 202. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 203. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. ASEAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 206. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 208. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 211. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 212. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 213. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. GCC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPEAN UNION LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 226. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 228. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 231. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 232. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 233. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. BRICS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 236. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 238. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 241. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 242. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 243. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 244. G7 LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 245. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 246. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 248. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 251. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 252. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 253. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. NATO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 255. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 256. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 257. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 259. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 261. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 262. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 263. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 264. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 267. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD MILLION)
  • TABLE 269. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 271. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 272. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2030 (USD MILLION)
  • TABLE 273. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 274. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 275. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)